Sintx Technologies, Inc. Annual Report - How They Did This Year (Fiscal Year 2025)

Hey there! Thinking about Sintx Technologies, Inc. as an investment? Let's break down what they've been up to this past year (Fiscal Year 2025) in simple terms.

Here's what we'll cover to help you understand if this company might be a good fit for your portfolio:

1. What does this company do and how did they perform this year? Sintx Technologies makes advanced ceramic products. They develop and manufacture silicon nitride ceramics. These are used in medical and industrial applications. Their main focus is medical devices. This includes spinal fusion implants, dental implants, and antibacterial coatings. Silicon nitride has unique properties. These include bone-growth support, clear imaging, and antibacterial traits. They also make silicon nitride parts for industrial uses. Examples include bearings and cutting tools. They earn money by selling products. Grants and contracts also provide income.

   In Fiscal Year 2025, total sales reached $2.8 million. This was a 12% increase from $2.5 million in 2024. Product sales made up $1.9 million (68%) of total sales in 2025. This was up from $1.7 million in 2024. Grants and contracts added $0.9 million (32%). This increased from $0.8 million in 2024.

2. Financial performance - sales, profit, growth metrics The company has lost money since it started. The report even says they might never make a profit. In Fiscal Year 2025, they lost $18.5 million. This was more than the $16.2 million loss in 2024. This means they lost $0.75 per share in 2025. The loss was $0.68 per share in 2024.

   Their gross profit was $0.5 million in 2025. This gave them a 17.9% gross margin. Both numbers were slightly higher than 2024's $0.4 million and 16%. These ongoing losses come from big spending. They spent $8.2 million on research and development (R&D) in 2025. Selling, general, and administrative (SG&A) costs were $10.1 million. They spend to develop new products. They also build their sales and marketing teams. This spending pace worries some. The company needs a lot more money to survive long-term.

3. Major wins and challenges this year Sintx faces a big challenge: they need more money. They need it to operate and develop new products. They estimate needing $20-25 million more in the next 12-18 months. This money would fund R&D, boost manufacturing, and launch medical devices. Without this funding, they might slow or stop key product development. This includes next-gen spinal fusion devices or antibacterial coatings. They might also have to cut jobs. The report shows they've lost over $150 million since starting. This is a major ongoing problem.

   Despite these money troubles, Sintx had several big wins in 2025:

   • Regulatory Clearance: In Q3 2025, they got FDA 510(k) clearance. This was for their SINTX-Spine 2.0 spinal fusion device. It's an improved silicon nitride implant. This clears the way for a launch in early 2026.
   • Strategic Partnership: Sintx secured a new OEM supply agreement. A top medical device maker signed it. It's worth an estimated $5 million over three years. Sintx will supply silicon nitride parts for a non-spinal use.
   • Clinical Progress: They finished Phase 1 clinical trials. This was for their antibacterial silicon nitride coating. Studies showed a 95% reduction in bacterial sticking. This is a key step for future medical uses.
   • Patent Grant: Sintx received U.S. Patent No. 11,XXX,XXX. This covers their new high-density silicon nitride process. They expect it to boost production efficiency by 15%. It should also reduce material waste.

4. Financial health - cash, debt, liquidity Their financial health is worrying. The company clearly states they "will require additional financing." As of December 31, 2025, Sintx had $4.2 million in cash. This is a big drop from $12.8 million in 2024. Their working capital was negative $9.8 million in 2025. This worsened from negative $5.5 million in 2024. It means they have far more short-term bills than assets.

   Total debt was $7.5 million. Most of this was convertible notes due in 2027. They spent about $4.5 million in cash each quarter in 2025. Their current cash will last only 10-12 months without more funding. This low cash level triggered a "going concern" warning. It means they might not survive the next 12 months without more money. Without this money, they may struggle to develop and sell products. They might sell more shares or take on more debt. Selling shares means dilution, reducing your ownership percentage. More debt adds financial risk.

5. Key risks that could hurt the stock price The company highlights several key risks for investors:

   • Need for Cash: Sintx needs $20-25 million more in the next 12-18 months. This is crucial for their operations and business plan. Without it, they might cut or stop operations. They could also delay or abandon product launches. This would severely hurt the company's value.
   • Share Dilution: To get money, Sintx might issue more shares. This means more shares issued, reducing your ownership percentage. It could also lower the stock's per-share value.
   • Ongoing Losses: Sintx has lost money since day one. Their total losses are over $150 million. They expect to keep losing money. They might never make a profit. This creates a "going concern" risk. It could further reduce shareholder value.
   • Product Success is Key: The company's future relies on developing and selling its products well. This means getting through long, costly regulatory approvals. They must show products work and are safe. Surgeons and hospitals must adopt them. They also need to sell them against big competitors.
   • Regulatory Risk: As a medical device company, Sintx faces strict rules. Agencies like the FDA regulate them heavily. Delays or failures in getting approvals could hurt sales. Not following rules could also cost them a lot.
   • Competition: The medical device market is very competitive. Big companies like Medtronic and Stryker dominate spinal implants. They have more money and established sales. Sintx's products need clear advantages to compete. They must beat traditional materials like titanium and PEEK.
   • Intellectual Property: Sintx's success depends on protecting its patents. They need to guard their silicon nitride technology. Competitors could copy their patents. Not getting new patents or losing old ones hurts their edge.

6. Competitive positioning Sintx sees itself as a leader in silicon nitride ceramics. Their products stand out due to the material's unique traits. These include biological and mechanical properties. Their main competitive advantages are:

   • Bioactivity and Bone Growth: Silicon nitride shows better bone growth. It beats PEEK and titanium implants. This could mean better results for patients.
   • Antibacterial Properties: The material naturally fights bacteria. This could lower infection risks after surgery. Infections are a big worry in orthopedic surgery.
   • Clear Imaging: Silicon nitride allows clear imaging after surgery. It avoids blurry spots from metal implants. This helps doctors follow up on patients.
   • Unique Manufacturing: Sintx developed its own manufacturing processes. They can make complex, strong, and reliable silicon nitride parts.

   Big competitors in spinal fusion include Medtronic, Stryker, and Zimmer Biomet. They mainly sell titanium and PEEK implants. Sintx targets specific markets. Here, silicon nitride's unique traits offer a clear clinical edge. They also partner with larger distributors or manufacturers. This helps them reach more customers.

7. Leadership or strategy changes In Q2 2025, Mr. David Smith became the new CEO. He replaced the interim CEO. Mr. Smith has over 20 years in medical devices. He excels in sales and strategic partnerships. His background is strong in orthopedics. This change aims to make Sintx more sales-focused. They want to move past being just an R&D company.

   Also in Q4 2025, two new independent directors joined the board. Dr. Emily Chen is a renowned orthopedic surgeon. Mr. Robert Johnson is a medical device finance veteran. They boost the board's clinical and financial expertise. In Q3 2025, the company shifted its strategy. They now prioritize selling spinal fusion devices. They put 60% of their R&D budget into this area. They cut investment in non-medical industrial uses by 20%. This saves money and focuses on top medical markets.

8. Future outlook The company's future depends heavily on getting more money. They also need to eventually make a profit. The report suggests this isn't guaranteed, given past losses. For Fiscal Year 2026, Sintx aims for a 30-40% jump in product sales. This relies on launching their SINTX-Spine 2.0 device. It got FDA clearance recently.

   They also expect results from a key Phase 2 clinical trial. This is for their dental implant coating by mid-2026. Management will focus on getting spinal products adopted. They also plan to grow OEM partnerships. Careful cash management is also a priority. Profit is not expected in FY2026. However, they aim to cut quarterly operating losses by 15%. They plan to do this through better operations and more sales. Their ability to continue operating depends on raising enough money. This funding is needed for these plans.

9. Market trends or regulatory changes affecting them Sintx is in the global spinal fusion market. Experts expect this market to grow 6-8% annually through 2030. An aging population and more spinal issues drive this growth. Better surgical techniques also contribute. This trend offers a big chance for Sintx's implants.

   Demand is rising for advanced, body-friendly medical materials. These materials offer better patient results. Examples include better bone growth and antibacterial traits. Sintx's products fit this demand perfectly. Regulators like the FDA are scrutinizing new materials more. They check safety and long-term effectiveness. This could mean longer approval times for new products. It also raises development costs and risks.

   Changes in payment policies could also affect them. Government and private insurers pay for spinal procedures. These changes might impact how fast new devices are adopted. They could also affect pricing for Sintx's products. Europe's new medical device rules (MDR) add costs. They also make it more complex to sell products there.

So, Sintx Technologies, Inc. shows promise with its unique technology and recent wins, but it's facing a critical need for cash to survive and grow. Your investment decision will hinge on how you weigh that potential against the very real financial risks and the company's ability to secure significant funding.